Conducting optimal clinical research is complex, resource intensive, and time consuming. A critical part of improving the evidence to guide our cardiovascular clinical practice is clinical trials’ methodologic design and choices of outcomes and endpoints. The Academic Research Consortia were created to define the most critical and standardized definitions of outcome measures. The Valve Academic Research Consortium (VARC) has substantially improved the quality of trials on aortic valve interventions through its multiple iterations. The latest VARC-3 definitions [1] aim to add more granularity and a patient focus to a rapidly evolving field and are particularly useful in providing a standard definition of bioprosthetic valve failure. This position statement considers the strengths and limitations of the VARC-3 document, identifies areas of concern, and proposes a way forward to further improve these definitions.

**REHOSPITALIZATION**

Rehospitalization, defined as any admission after the index hospitalization or study enrollment, was added to the VARC-3 recommended endpoints. Given the range of challenges, we do not endorse the blanket inclusion of rehospitalization as a component of the primary composite outcome in comparative effectiveness trials of SAVR versus TAVI. The primary outcome of a trial should be the variable capable of providing the most clinically relevant and convincing evidence directly related to the primary objective of the experimental study (randomized clinical trial) [2]. It is unclear whether hospital readmission rates correlate with major morbidity and mortality outcomes. In addition, rehospitalizations outnumber mortality events, especially in short follow-up trials that include patients with low periprocedural risks, and quickly become the primary driver of the composite endpoint.

Time-to-event analyses are powered by the event count, and the rationale for including rehospitalization in the primary composite outcome for low-risk trials is to address the challenge created by the sparse number of conventional events. However, rehospitalization was not included in the primary composite endpoint of the Medtronic Evolut Low Risk trial [3]. The 1-year results of the Placement of Aortic Transcatheter Valves (PARTNER)-3 trial showed the superiority of transcatheter aortic valve implantation (TAVI) using this primary composite outcome driven by substantially more rehospitalizations in the surgical aortic valve replacement (SAVR) arm [4]. At 2 years of follow-up, however, this superiority was waning. The difference in hard clinical outcomes (the composite of all-cause death or stroke) reduced from a hazard ratio of 0.34 (95% confidence interval,
The VARC-3 definitions of MI without clinical confirmation is suboptimal in surgical interventions. SAVR requires a period of ischemia during aortic cross-clamping and is inherently associated with a release of cardiac enzymes that do not represent a MI. There are two inconsistent definitions for MI in the cardiovascular research literature. The modified Society for Cardiovascular Angiography and Intervention definitions for type 5 (periprocedural) MI rely solely on biomarkers 10 or more times UNL without clinical correlation to diagnose a type 5 MI. In contrast, the regularly updated Universal Definitions of Myocardial Infarction, which was developed by the leading societies in the field, including the European Society of Cardiology, American College of Cardiology, American Heart Association, and World Heart Federation, recognizes the pitfalls of isolated elevated biomarkers and requires clinical confirmation. Available data suggest that periprocedural MIs were more prognostically significant when diagnosed with Universal Definitions of Myocardial Infarction than the modified Society for Cardiovascular Angiography and Intervention definitions for surgical patients [6–8]. Whereas for valve thrombosis and bleeding a clinical confirmation has appropriately been advocated by the VARC-3 authors, we propose that a clinical validation for perioperative MI should also be advocated. Further clarity and consistency in the VARC-3 document should be provided, and we would endorse requiring clinical confirmation.

NEW LEFT BUNDLE BRANCH BLOCK

The need for a new permanent pacemaker has been added to the early composite safety, and the VARC-3 authors should be congratulated. Although clinical evidence has been growing regarding the negative impact of new left bundle branch block [9], they state that “new LBBB was not included in the safety composite, but VARC-3 recognizes that this may become an important endpoint to consider in the future.” We believe this is a missed opportunity and suggest considering new left bundle branch block as an endpoint in the VARC-3 document.

PRESCRIPTION OF HEART TEAM AND MULTIDISCIPLINARY COLLABORATION

The previous iterations of VARC were also simultaneously published in the surgical journals (European Journal of Cardiothoracic Surgery, Journal of Thoracic and Cardiovascular Surgery, and The Annals of Thoracic Surgery), indicating their importance of the concept of the entire Heart Team. However, the VARC-3 definitions manuscript was simultaneously published in the European Heart Journal and the Journal of the American College of Cardiology, two of the most prominent cardiology journals. Moreover, the writing committee...
was composed of only two practicing cardiac surgeons among 23 authors. Contrary to VARC and VARC-2, regulators were not among the authorship group of this iteration.

The authors of VARC-3 are renowned experts in the field of valvular heart disease. Content expertise for such definitions is desirable. A more diverse writing group, with full representation of stakeholders, would be desirable and may help mitigate issues related to the duality of interests. It would be valuable that the VARC-3 authors continue this collaboration by publishing simultaneously in surgical journals to promote the critical culture of the multidisciplinary heart team decision making. We further recommend a review and endorsement process including societies and individuals with minimal relationships with industry and no direct involvement in the relevant trials’ leadership related to the definitions.

THE PATH FORWARD

This position statement recognizes the contribution and positive progress as well as substantive concerns regarding the recent VARC-3 document on aortic valve replacement (surgical and transcatheter) proposed definitions and endpoints. In trials comparing SAVR and TAVI, we would favor focusing on death and stroke as the primary endpoint and reserving other endpoints as secondary. As patient advocates, the heart team approach with thoughtful surveillance with regards to long-term clinical outcomes and prosthetic performance should be enthusiastically embraced.

Trials on human subjects should keep as a central tenet the altruism and generosity of our patients who participate in research to advance our field by applying sound, unbiased, and reasonable methodologies. We applaud the VARC work through the years in improving the definitions of outcome measures and study endpoints, which has helped to improve the conduct and reporting of clinical trials. There are many important contributions from the VARC-3 project; however, some important areas of concern require clarity and improvement. We recommend the development of a new set of definitions, with fully disclosed relationships with industry and including stakeholders from noninvasive cardiology, surgery, regulators, and patient representatives, and with a more diverse, worldwide involvement. The definitions in VARC-3 should be a living document, and we would encourage adoption of the constructive suggestions highlighted in this position statement as we look to future clinical research.

Funding

Nicholas Freemantle receives institutional support from EACTS.

Conflict of interest: Dr Szeto discloses a financial relationship with Edwards and Medtronic; Dr Thourani with Abbott Vascular, Boston Scientific, CryoLife, Edwards Lifesciences, Medtronic, Shockwave, and JenaValve; Dr Malaisrie with Edwards, CryoLife, and Medtronic; and Dr Moon with Medtronic.

REFERENCES